Status:
COMPLETED
Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Asia. The aim of this trial is to investigate the pharmacokinetics after a single dose of insulin detemir in healthy Chinese male subjects.
Eligibility Criteria
Inclusion
- Body mass index (BMI) between 18 and 25 kg/m\^2 (both inclusive)
- Fasting plasma glucose maximum 6 mmol/L
- Non-smoker
- Considered generally healthy upon completion of medical history, physical examination and laboratory assessments, as judged by the Investigator
Exclusion
- Known or suspected allergy to trial product(s) or related products
- Previous participation in this trial. Participation is defined as randomisation
- Receipt of any investigational drug within the last three months prior to this trial
- History of alcohol or drug abuse
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01498939
Start Date
August 1 2007
End Date
September 1 2007
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100032